Journal article
Christopher D. Barrett, H. Moore, N. Vigneshwar, Sanjeev Dhara, James G. Chandler, M. Chapman, A. Sauaia, E. Moore, M. Yaffe
Journal of Trauma and Acute Care Surgery, 2020
Journal of Trauma and Acute Care Surgery, 2020
Semantic Scholar
DOI
PubMed
Cite
Cite
APA
Click to copy
Barrett, C. D., Moore, H., Vigneshwar, N., Dhara, S., Chandler, J. G., Chapman, M., … Yaffe, M. (2020). Plasmin TEG Rapidly Identifies Trauma Patients at Risk for Massive Transfusion, Mortality and Hyperfibrinolysis: A Diagnostic Tool to Resolve an International Debate on TXA? Journal of Trauma and Acute Care Surgery.
Chicago/Turabian
Click to copy
Barrett, Christopher D., H. Moore, N. Vigneshwar, Sanjeev Dhara, James G. Chandler, M. Chapman, A. Sauaia, E. Moore, and M. Yaffe. “Plasmin TEG Rapidly Identifies Trauma Patients at Risk for Massive Transfusion, Mortality and Hyperfibrinolysis: A Diagnostic Tool to Resolve an International Debate on TXA?” Journal of Trauma and Acute Care Surgery (2020).
MLA
Click to copy
Barrett, Christopher D., et al. “Plasmin TEG Rapidly Identifies Trauma Patients at Risk for Massive Transfusion, Mortality and Hyperfibrinolysis: A Diagnostic Tool to Resolve an International Debate on TXA?” Journal of Trauma and Acute Care Surgery, 2020.
BibTeX Click to copy
@article{christopher2020a,
title = {Plasmin TEG Rapidly Identifies Trauma Patients at Risk for Massive Transfusion, Mortality and Hyperfibrinolysis: A Diagnostic Tool to Resolve an International Debate on TXA?},
year = {2020},
journal = {Journal of Trauma and Acute Care Surgery},
author = {Barrett, Christopher D. and Moore, H. and Vigneshwar, N. and Dhara, Sanjeev and Chandler, James G. and Chapman, M. and Sauaia, A. and Moore, E. and Yaffe, M.}
}
Abstract
BACKGROUND Trauma patients with hyperfibrinolysis and depletion of fibrinolytic inhibitors(DFI) measured by thrombelastography(TEG) gain clot strength with TXA, but TEG results take nearly an hour. We aimed to develop an assay, plasmin TEG(P-TEG), to more expeditiously stratify risk for massive transfusion(MT), mortality and hyperfibrinolysis.
METHODS Trauma patients(n=148) were assessed using TEG assays without exogenous additives(rapid/native), with exogenous plasmin(P-TEG) or tissue plasminogen activator(tPA TEG). The plasmin dose used does not effect healthy control LY30 but causes shortened R-time relative to native TEG(P-TEG R-time<native TEG R-time considered P-TEG "negative"). If P-TEG R-time ≥ native TEG R-time the patient was considered P-TEG "positive." Each assay's ability to predict MT, mortality, and (risk for) hyperfibrinolysis was determined. Chi-square and Mann-Whitney U tests were used to compare categorical and continuous variables, respectively. Results reported as median(±IQR), or n(%).
RESULTS P-TEG provided results faster than all other assays(4.7min ±2.5-9.1), ~11-fold faster than Rapid-TEG LY30(54.2min ±51.1-58.1;p<0.001). P-TEG positive patients had >4-fold higher MT rate(30% vs 7%;p=0.0015) with AUROC 0.686(p=0.028), >4-fold higher 24 hour mortality(33.3% vs 7.8%;p=0.0177), >2-fold higher 30 day mortality(35% vs. 16.4%;p=0.0483), higher rates of DFI(55 vs 18%;p<0.001), and a trend towards elevated D-dimer(19.9 vs 3.3 μg/mL;p=0.14). P-TEG was associated with hyperfibrinolysis on Rapid-TEG LY30 at the 7.6% threshold(p=0.04) but not the 3% threshold(p=0.40). P-TEG performed best in relation to DFI, with a PPV of 58% and NPV of 81%. When combined with tPA TEG TMA, P-TEG outperformed R-TEG LY30 for predicting MT(AUROC 0.811 vs 0.708).
CONCLUSIONS Within 5 minutes P-TEG can stratify patients at highest risk for MT, mortality, and risk for hyperfibrinolysis. In composite with tPA TEG TMA, P-TEG outperforms Rapid-TEG LY30 for predicting MT and does so 4x faster(12.7min vs. 54.1min). The rapid results of P-TEG may be useful for those who practice selective TXA administration to maximize TXA's time-dependent efficacy.
LEVEL OF EVIDENCE Level IVDiagnostic Test.